Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
RAMPART
Renal Adjuvant MultiPle Arm Randomised Trial
- NCT03288532 ↗
- Recruiting
- University College, London
- Deep
We haven't built an HCP commentary report on RAMPART (durvalumab; durvalumab plus tremelimumab in intermediate- or high-risk resected renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RAMPART so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 106 | |
| YouTube | 41 | |
| Podcasts | 38 | |
| X videos | 8 |
The trial
ClinicalTrials.gov- Official title
- An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Durvalumab; Tremelimumab
- Arms
- Arm A (active monitoring) · No intervention
- Arm B (durvalumab monotherapy) · Experimental
- Arm C (durvalumab + tremelimumab) · Experimental
- Enrollment
- 1,750 (estimated)
- Primary outcomes
- Disease Free Survival (DFS): Arm C vs A
- Disease Free Survival (DFS): Arm B vs A
- Overall Survival (OS): Arm C vs A (high risk patients only)
- Overall Survival (OS): Arm B vs A (high risk patients only)
- Sponsor
- University College, London with AstraZeneca, Kidney Cancer UK, Cancer Research UK
- Start
- Jul 19, 2018
- Primary completion
- Jul 1, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT03288532 · updated Sep 7, 2020
Publications
linked from the registry- Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Harrison D, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Parmar MKB, Larkin J, Meade A. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials. 2021 Sep;108:106482. doi: 10.1016/j.cct.2021.106482. Epub 2021 Sep 16. PubMed 34538402
- Meade A, Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Harrison DJ, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Larkin J, Parmar MKB. RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. Contemp Clin Trials. 2021 Sep;108:106481. doi: 10.1016/j.cct.2021.106481. Epub 2021 Sep 16. PubMed 34538401
- Marconi L, Sun M, Beisland C, Klatte T, Ljungberg B, Stewart GD, Dabestani S, Choueiri TK, Bex A. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clin Genitourin Cancer. 2021 Apr;19(2):e92-e99. doi: 10.1016/j.clgc.2020.12.005. Epub 2021 Jan 7. PubMed 33526329